Recommend FRX (Forest Labs), Drug sector for folio.
"However, if investors really want something to be happy about, the story seems to be Namenda. According to the Alzheimer's Association, by 2010, more than 5.5 million Americans will have the disease.
Other medications to treat Alzheimer's include Pfizer's (NYSE: PFE) Aricept, Novartis' (NYSE: NVS) Exelon, and Shire Pharmaceuticals (Nasdaq: SHPGY) and Johnson & Johnson's (NYSE: JNJ) Reminyl. However, Namenda had already distinguished itself by treating a niche of patients other drugs did not -- moderate-to-severe Alzheimer's patients."
quicken.com
Forest Labs' High Hopes
Email this page
Format for printing
Become a Fool!
Reuse/Reprint
Related Links
Motley Fool Take Archive
Alzheimer's Drug Deemed Safe
Discussion Boards
The Motley Fool Take
Pharmaceuticals
By Alyce Lomax
January 21, 2004
"Forest Laboratories (NYSE: FRX) gave investors what seemed like a one-two punch of good news on Tuesday. First, it reported higher third-quarter profits, greatly linked to sales of its antidepressants Celexa and Lexapro. Later in the day, it said The Journal of the American Medical Association backed up the effectiveness of Namenda (memantine), its high-profile Alzheimer's treatment that was approved last October." - The Motley Fool "Forest Lab's High Hopes" Jan. 21, 2004 |
